FINWIRES · TerminalLIVE
FINWIRES

Cygnus Metals to Be Acquired by Central Asia Metals in AU$232 Million All-Scrip Deal

By

Cygnus Metals (ASX:CY5) agreed to be acquired by Central Asia Metals in an all-scrip deal that values each Cygnus share at AU$0.176, implying an equity value for the company of around AU$232 million, according to a late Tuesday filing with the Australian bourse.

Under a definitive scheme implementation deed, Cygnus shareholders will receive 0.06 new Central Asia Metals share for each Cygnus share held.

Existing Central Asia Metals shareholders will own about 70% of the company's enlarged fully diluted issued share capital after the deal, while Cygnus shareholders will own the remaining 30%.

The transaction will give Central Asia Metals a flagship development-stage asset through a 100% interest in Canada's Chibougamau copper-gold project.

Related Articles

Asia

Scales Declares Final Dividend for 2025

Scales (NZE:SCL) declared a final dividend of NZ$0.125 per share for full year 2025, payable on July 9 to shareholders of record as of June 25, according to a Wednesday filing with the New Zealand bourse.The company paid a dividend of NZ$0.0775 per share in the prior corresponding period, an earlier filing showed.

$NZE:SCL
Asia

Telix Pharmaceuticals, United Imaging Healthcare Sign MOU for US Theranostics Collaboration

Telix Pharmaceuticals (ASX:TLX) and United Imaging Healthcare North America entered into a memorandum of understanding (MOU) to evaluate a strategic research partnership in the US focused on developing integrated theranostics technologies that combine diagnostics and targeted therapy, Telix said Tuesday after hours.The partnership will evaluate integrating United Imaging's imaging systems, software, connectivity, and artificial intelligence (AI) tools with the company's molecular imaging portfolio and clinical protocols to enhance theranostic workflows.Key focus areas include improving integration of imaging and radiopharmaceutical workflows, standardizing protocol-driven imaging across sites, enhancing treatment planning and patient monitoring, and developing AI-enabled clinical decision support tools.The initial focus will be on TLX101-Px, a positron emission tomography imaging candidate, with opportunities to expand into additional products and markets, as well as pilot programs and protocol optimization efforts.

$ASX:TLX
Asia

Peter Warren Automotive Holdings' Wakeling Deal Faces ACCC Phase Two Competition Review

Peter Warren Automotive Holdings' (ASX:PWR) planned purchase of 30 new car dealership sites from Wakeling Automotive Group will undergo a detailed phase two Australian Competition and Consumer Commission (ACCC) review after the competition regulator raised concerns about the deal's potential impact on market competition, according to an Australian bourse filing on Tuesday after market hours.The regulator did not approve the acquisition during its phase one assessment, saying that the merged company would own 25 of the region's 33 new car dealerships, per the filing. It is assessing how the deal could affect competition in new vehicle sales, as well as servicing and repair services.The ACCC has yet to make a final decision and is inviting public submissions until June 16, the filing added. The phase two review could take up to 90 business days.In a separate filing, Peter Warren Automotive said the companies will continue to work with the ACCC to address any concerns arising during the phase two review.

$ASX:PWR